Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Pfizer ponders spinning off its Consumer Healthcare division

The viagra maker is considering whether it can release value by spinning off some or all of its consumer healthcare business, which includes brands such as Advil, Chapstick and Preparation H.
Advil
Pfizer could make piles of money selling brands such as Preparation H and Advil

Drugs giant Pfizer Inc (NYSE:PFE) is mulling whether to put its consumer healthcare brands on the block.

The company is considering a range of options, including a full or partial separation of the Consumer Healthcare business from Pfizer through a spin-off, sale or other transaction.

Pfizer Consumer Healthcare is a leading player in the largest OTC [over the counter] categories, with iconic brands, robust retail partnerships, global reach and strong fundamentals,” said Ian Read, Pfizer’s chairman and chief executive officer.

“Although there is a strong connection between Consumer Healthcare and elements of our core biopharmaceutical businesses, it is also distinct enough from our core business that there is potential for its value to be more fully realized outside the company. By exploring strategic options, we can evaluate how best to fuel the future success and expansion of Consumer Healthcare while simultaneously unlocking potential value for our shareholders,” he added.

Pfizer’s consumer brands include Advil, Chapstick and Preparation H.

Shares in the Viagra maker were up 1% at US$36.52 in pre-market trading. 

View full PFE profile View Profile

Pfizer Timeline

Article
November 23 2015

Related Articles

newspaper with word cancer magnified
January 15 2018
"In our view, the potential for SCIB1 [Scancell's skin cancer treatment], as already demonstrated by the survival data, is remarkable," said one broker recently
test tubes
January 22 2018
Under former chief executive Peter George and his successor Shaun Chilton, it has been transformed via a series of well-judged, quickly integrated and, crucially, cash generative acquisitions
picture of human skeleton
January 16 2018
Tissue Regenix is funding the acquisition with a placing at 10p to raise £40mln

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use